Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.96 USD
+1.38 (2.14%)
Updated May 10, 2024 04:00 PM ET
After-Market: $65.92 -0.04 (-0.06%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GILD 65.96 +1.38(2.14%)
Will GILD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Other News for GILD
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine